GHRP-1

Overview

GHRP-1 (Growth Hormone Releasing Peptide 1) is a synthetic hexapeptide developed by Cyril Y. Bowers and colleagues as part of the pioneering research program at Tulane University that identified a series of synthetic peptides capable of releasing growth hormone (GH) from the pituitary through a mechanism distinct from that of growth hormone releasing hormone (GHRH). This work, spanning from the late 1970s through the 1990s, established the category of "growth hormone secretagogues" (GHS) and ultimately led to the discovery of the orphan receptor GHS-R1a (the growth hormone secretagogue receptor, subsequently deorphanized by the identification of ghrelin as its endogenous ligand in 1999).

Chronologically, GHRP-1 preceded the better-known GHRP-2 and GHRP-6, and it served as a template from which the later, more potent and more selective analogs were derived. GHRP-1 is structurally related to the earliest Met-enkephalin-derived GH-releasing analogs that Bowers and colleagues initially synthesized, and it reflects an important middle stage in the medicinal chemistry trajectory from opioid-derived lead compounds to the modern family of GHS peptides (GHRP-2, GHRP-6, hexarelin, ipamorelin) and small-molecule mimetics (MK-0677/ibutamoren).

GHRP-1 is considered a historical research peptide of interest primarily for its place in the discovery trajectory of the GHS/ghrelin system. It is less studied than the subsequent analogs and has been largely superseded by them in research applications, but it retains educational value as part of the story of how a distinct GH-releasing axis was uncovered.

Structure/Sequence

GHRP-1: H-Ala-His-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂ (as reported in Bowers' original literature for GHRP-1)

Note: Different sources have used the "GHRP-1" designation for slightly different sequences; the most widely cited is a heptapeptide variant. A commonly listed hexapeptide form is:

GHRP-1 (hexapeptide form): Ala-His-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂

• Length: 6-7 amino acids depending on form
• C-terminal amidation: Essential for receptor activity
• D-amino acids: Incorporation of D-β-naphthylalanine (D-Nal) and D-Phe confers peptidase resistance
• Non-natural residues: D-β-Nal is a bulky unnatural amino acid that enhances GHS-R binding

Key Structural Features

• N-terminal Ala-His: Distinguishes GHRP-1 from GHRP-2 (which begins D-Ala-D-β-Nal)
• D-Nal residue: Conserved across the GHRP series; critical for high-affinity binding
• Trp residue: Hydrophobic contact shared with later GHRPs
• D-Phe-Lys-NH2 C-terminus: Structural signature of the early GHRP family

Relationship to Other GHRPs

The GHRP family descends from Met-enkephalin (YGGFM) with systematic medicinal chemistry modifications:

• Initial opioid-derived analogs → GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2)
• GHRP-6 → GHRP-1 (Ala substitution at position 1)
• GHRP-1 → GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2; more potent)
• GHRP-2 → Hexarelin (2-methyl-Trp substitution)
• Parallel track → Ipamorelin (Aib-His-D-β-Nal-D-Phe-Lys-NH2; selective GH without ACTH/cortisol)

Mechanism of Action

GHS-R1a Agonism

GHRP-1, like all GHRP-family peptides, acts as an agonist at the growth hormone secretagogue receptor GHS-R1a:

• Gq-coupled GPCR
• Activates phospholipase C → IP3/DAG → calcium release in somatotropes
• Stimulates GH release from pituitary independent of GHRH signaling
• Synergizes with GHRH when co-administered

GH Release

• Stimulates pulsatile GH release
• Acts both directly on pituitary somatotropes and indirectly through hypothalamic GHRH neurons
• Synergy with exogenous GHRH — combined administration produces supra-additive GH release
• Suppressed by somatostatin tone in vivo

Non-GH Effects

Like other early GHRPs, GHRP-1 has modest effects on:

• ACTH and cortisol: Often elevated (a limitation addressed by later selective GHS like ipamorelin)
• Prolactin: Modest increase
• Appetite: GHS-R1a activation stimulates appetite (ghrelin-like effect)

Relationship to Endogenous Ghrelin

When ghrelin was identified in 1999 as the endogenous ligand of GHS-R1a, it became clear that all the GHRP family peptides had been acting at the receptor for a previously unknown endogenous hormone. This retrospectively explained the synergy with GHRH, the appetite-stimulating effects, and the physiological significance of the GHS axis.

Research Summary

Common Discussion Topics

1. Historical context in GHS discovery — GHRP-1 is part of a systematic medicinal chemistry program that inadvertently revealed the existence of an entire endocrine axis. The sequence of GHRP-1 → GHRP-6 → GHRP-2 → hexarelin → MK-0677 → deorphanization of GHS-R1a → discovery of ghrelin illustrates how pharmacological tools can precede and enable identification of endogenous systems.

2. Met-enkephalin origin — The remarkable observation that systematic modification of an opioid pentapeptide (Met-enkephalin) produced a family of GH-releasing agents reflects the breadth of chemical space explored by medicinal chemistry of that era and the unpredictable pharmacology of modified peptide scaffolds.

3. Superseded by later analogs — GHRP-1 is largely eclipsed in modern research by GHRP-2, GHRP-6, hexarelin, and ipamorelin, each offering improved potency, selectivity, or metabolic profiles. GHRP-1 retains value mainly as a historical and comparative reference.

4. GHRH synergy — The synergy between GHRPs (including GHRP-1) and GHRH reflects two distinct mechanistic inputs to somatotrope GH release. This synergy is a well-established feature of the GH axis and informs research approaches combining GHRH analogs with GHS (e.g., sermorelin or CJC-1295 with GHRPs).

5. Selectivity limitations — Early GHRPs including GHRP-1 raise ACTH, cortisol, and prolactin in addition to GH. The later development of ipamorelin as a GH-selective secretagogue addressed these off-target effects.

Related Compounds

• GHRP-2 — later, more potent analog of the same family
• GHRP-6 — another member of the early GHRP series
• Hexarelin — derivative with 2-methyl-Trp substitution
• Ipamorelin — GH-selective GHS developed after the early GHRPs
• Ghrelin — endogenous ligand of the shared GHS-R1a receptor
• Sermorelin — GHRH(1-29) analog used synergistically with GHRPs